Insmed 2022 Investor Presentation

Insmed is a biopharmaceutical company focused on the development and commercialization of novel therapies. The presentation outlines the company's lead product ARIKAYCE (amikacin liposome inhalation suspension) for treating serious infections, along with its pipeline candidates including brensocatib and TPIP. Key discussion includes regulatory strategies, market opportunities, and product commercialization efforts.